Introduction

According to the 2011–12 Australian Health Survey, approximately 63% of Australian adults have dyslipidaemia.1 One in three of these Australians have abnormally elevated low density lipoprotein cholesterol (LDL-C) and one in three have elevated triglycerides.1 Lipid disorders (see Table 1) are the sixth most frequently managed conditions in Australian general practice.2,3

Learning objectives

After successful completion of this CPD activity, pharmacists should be able to:

  • Identify risk factors for hyperlipidaemia
  • Discuss pharmacological management of hyperlipidaemia
  • Outline the role of the pharmacist in advising patients on non-pharmacological and pharmacological management of hyperlipidaemia

Competency standards addressed (2016): 1.1, 1.5, 1.6, 3.5

Accreditation number: CAP1911CDMNR

Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.  

Statins are among the top two most commonly dispensed medicines on the Pharmaceutical Benefits Scheme (PBS).2,3 In the last decade there have been significant improvements in the understanding of LDL-C metabolism, identification of novel therapeutic targets and medicines as well as an increased understanding of the r

THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.